Clinicopathologically supported photodistributed hyperpigmentation with associated nail changes during adagrasib therapy

Clicks: 19
ID: 327669
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #185 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Adagrasib is a selective KRAS G12C inhibitor increasingly used in advanced malignancies and is associated with a range of cutaneous adverse effects. However, pigmentary changes remain rarely reported. We report a patient with recurrent KRAS G12C–mutant non–small cell lung cancer who developed photodistributed hyperpigmentation with associated nail matrix changes following adagrasib therapy.
Reference Key
openalex_W7208778466 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag382
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.